https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-01 / Medicine (Baltimore) 2020 Feb;99(8):e18889
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-01 / Medicine (Baltimore) 2020 Feb;99(8):e188892020-02-01 00:00:002020-02-01 00:00:00Substantial tumor regression in prostate cancer patient with extensive skeletal metastases upon Immunotherapy (APCEDEN): A case report
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-01 / J Immunother Cancer 2020 02;8(1)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-01 / J Immunother Cancer 2020 02;8(1)2020-02-01 00:00:002020-02-01 00:00:00TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-01-31 / Biomed. Pharmacother. 2020 May;125:109966
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-01-31 / Biomed. Pharmacother. 2020 May;125:1099662020-01-31 00:00:002020-01-31 00:00:00Interferon-α2b enhances survival and modulates transcriptional profiles and the immune response in melanoma patients treated with dendritic cell vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-01-27 / Expert Opin Biol Ther 2020 03;20(3):253-262
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-01-27 / Expert Opin Biol Ther 2020 03;20(3):253-2622020-01-27 00:00:002020-01-27 00:00:00Novel immunotherapy combinations for genitourinary cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-01-24 / Cancer Immunol. Immunother. 2020 Mar;69(3):477-488
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-01-24 / Cancer Immunol. Immunother. 2020 Mar;69(3):477-4882020-01-24 00:00:002020-01-24 00:00:00Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-01-24 / Hum Vaccin Immunother 2020 Oct;16(10):2318-2327
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-01-24 / Hum Vaccin Immunother 2020 Oct;16(10):2318-23272020-01-24 00:00:002020-01-24 00:00:00Suppression of TGF-β and IL-10 receptors on self-differentiated dendritic cells by short-hairpin RNAs enhanced activation of effector T-cells against cholangiocarcinoma cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-01-23 / Oncol Lett 2020 Mar;19(3):2422-2430
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-01-23 / Oncol Lett 2020 Mar;19(3):2422-24302020-01-23 00:00:002020-01-23 00:00:00Breast cancer stem cell RNA-pulsed dendritic cells enhance tumor cell killing by effector T cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-01-23 / Pharmaceutics 2020 Jan;12(2)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-01-23 / Pharmaceutics 2020 Jan;12(2)2020-01-23 00:00:002020-01-23 00:00:00Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells-An Update
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-01-16 / NPJ Vaccines 2020;5:5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-01-16 / NPJ Vaccines 2020;5:52020-01-16 00:00:002020-08-26 13:53:37Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-01-01 / Cytotherapy 2020 01;22(1):6-15
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-01-01 / Cytotherapy 2020 01;22(1):6-152020-01-01 00:00:002020-08-26 13:55:22Prophylactic dendritic cell vaccination controls pancreatic cancer growth in a mouse model
